Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Two different bispecific hybrid antibodies were generated by cell fusion of pairs of existing hybrid-myeloma cell lines. Both hybrid antibodies had similar specificity for human CD3 and mouse Thy-1 but differed in the isotypes of the immunoglobulin heavy chains. Hybrid HA2b/2b was a hybrid between a rat IgG2b (CD3) and a rat IgG2b anti-Thy-1, whereas HA2b/2c was a hybrid between the same rat IgG2b (CD3) and a rat IgG2c anti-Thy-1. Both hybrid antibodies were found to be very potent in inducing the killing of Thy-1-positive targets by human T-cell blasts, with the hetero-hybrid HA2b/2c showing a higher titer. T-cell blasts generated from resting peripheral blood mononuclear cells by a novel mitogenic antibody, YTH361, were exploited as effector cells. In addition to the CD3-dependent killing, the rat IgG2b anti-Thy-1 antibody and the hybrid antibody HA2b/2b but not the rat IgG2c anti-Thy-1 or the hybrid antibody HA2b/2c were also able to elicit antibody-dependent cell-mediated cytotoxicity (ADCC). This ADCC was inhibited by an anti-FcRlow (CD16) monoclonal antibody, which suggests that these effectors were K-cells. Toxicity toward the T-cell blast effector population was also observed, but in this instance the hetero-hybrid HA2b/2c had a lower cytotoxic titer. In conclusion, mixed isotype hybrid antibodies may have some advantages for eliciting T-cell-mediated killing of tumor cell targets by exhibiting a better therapeutic ratio of target cell to effector cell cytotoxicity.


Journal article


J Natl Cancer Inst

Publication Date





1393 - 1401


Animals, Antibodies, Monoclonal, Cells, Cultured, Complement System Proteins, Cytotoxicity, Immunologic, Humans, Hybridomas, Immunoglobulin G, Immunoglobulin Heavy Chains, Mice, Rats, Receptors, Fc, T-Lymphocytes